AZ signs up for access to Compugen’s pipeline
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
Bispecific antibodies are genetically engineered to simultaneously bind to two (bi-specific) or more (multi-specific) different types of antigen. They enable multiple mechanisms of action for treating disease within a single molecule.
Under the deal, MedImmune has gained the right to create multiple products, and will be solely responsible for all research, development and commercial activities.
In return, Compugen will receive a $10 million upfront payment and potentially up to $200 million in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales.
Read more: http://www.pharmatimes.com/news/az_signs_up_for_access_to_compugens_pipeline_1230099
Bispecific antibodies are genetically engineered to simultaneously bind to two (bi-specific) or more (multi-specific) different types of antigen. They enable multiple mechanisms of action for treating disease within a single molecule.
Under the deal, MedImmune has gained the right to create multiple products, and will be solely responsible for all research, development and commercial activities.
In return, Compugen will receive a $10 million upfront payment and potentially up to $200 million in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales.
Read more: http://www.pharmatimes.com/news/az_signs_up_for_access_to_compugens_pipeline_1230099
